NASDAQ:RCKT - Rocket Pharmaceuticals Stock Price, Forecast & News

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.11. View Rocket Pharmaceuticals' Earnings History.

Rocket Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Rocket Pharmaceuticals.

8 equities research analysts have issued 12-month price targets for Rocket Pharmaceuticals' stock. Their forecasts range from $27.00 to $42.00. On average, they expect Rocket Pharmaceuticals' stock price to reach $35.80 in the next year. This suggests a possible upside of 71.8% from the stock's current price. View Analyst Price Targets for Rocket Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rocket Pharmaceuticals.

Media stories about RCKT stock have been trending negative on Thursday, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Rocket Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Rocket Pharmaceuticals.

Some companies that are related to Rocket Pharmaceuticals include Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), FibroGen (FGEN), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Alkermes (ALKS), Evotec (EVTCY), SAGE Therapeutics (SAGE), Myokardia (MYOK) and Genmab A/S (GMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Alibaba Group (BABA), Energy Transfer LP Unit (ET), Viking Therapeutics (VKTX), Home Depot (HD), Pfizer (PFE), Amgen (AMGN), MEI Pharma (MEIP), NVIDIA (NVDA) and Honeywell International (HON).

Rocket Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (2.81%), State Street Corp (1.94%), Millennium Management LLC (0.10%), Squarepoint Ops LLC (0.07%), Comerica Bank (0.06%) and Zeke Capital Advisors LLC (0.04%). Company insiders that own Rocket Pharmaceuticals stock include David P Southwell, Gaurav Shah, Kinnari Patel, Naveen Yalamanchi and Rtw Investments, Lp. View Institutional Ownership Trends for Rocket Pharmaceuticals.

RCKT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp, Squarepoint Ops LLC and Barclays PLC. Company insiders that have sold Rocket Pharmaceuticals company stock in the last year include David P Southwell and Gaurav Shah. View Insider Buying and Selling for Rocket Pharmaceuticals.

RCKT stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, California Public Employees Retirement System, Zeke Capital Advisors LLC, Meeder Asset Management Inc., Comerica Bank, Tower Research Capital LLC TRC, Metropolitan Life Insurance Co NY and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include Kinnari Patel and Rtw Investments, Lp. View Insider Buying and Selling for Rocket Pharmaceuticals.

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RCKT stock can currently be purchased for approximately $20.84.

Rocket Pharmaceuticals has a market capitalization of $1.05 billion. The biotechnology company earns $-74,520,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Rocket Pharmaceuticals employs 33 workers across the globe.View Additional Information About Rocket Pharmaceuticals.

The official website for Rocket Pharmaceuticals is http://www.rocketpharma.com/.

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]